Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HALOS: ION582 in Angelman Syndrome
NCT05127226Phase 2Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Mar 2029
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 6
01
Overview
Phase 2, open-label trial of obudanersen in Angelman syndrome (AS) (10 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Adverse Events at 81 weeks. Started Dec 2021; status: active, not recruiting.
02
Drugs
obudanersen
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on NCT05127226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05127226.